Preview

Пульмонология

Расширенный поиск

Будесонид / формотерол – ингалятор для базисного лечения и купирования симптомов бронхиальной астмы (стратегия SMART)

https://doi.org/10.18093/0869-0189-2007-0-6-87-92

Полный текст:

Об авторе

Н. П. Княжеская
Кафедра пульмонологии ФУВ ГОУ ВПО РГМУ
Россия
Москва


Список литературы

1. Global Initiative for Asthma. Workshop report [Электронный ресурс], 2006. Доступ: http://www.ginasthma.com/download.asp?intId=217

2. O'Byrne P.M., Barnes P.J., Rodriguez2Roisin R. et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. 2001; 164: 1392–1397.

3. Lundback B., Ronmark E., Lindberg A. et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir. Med. 2006; 100 (1): 2–10.

4. Bateman E.D., Boushey H.A., Bousquet J. et al. Pedersen SE for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.

5. Rabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur. Respir. J. 2000; 16: 802–807.

6. Rabe K.F., Adachi M., Lai C.K. et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J. Allergy Clin. Immunol. 2004; 114: 40–47.

7. Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol And Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337: 1405–1411.

8. Kips J.C., O'Connor B.J., Inman M.D. et al. A long-termed study of the antiinflammatory effect of low-dosed budesonide plus formoterol versus high-dosed budesonide in asthma. Am. Respir. Crit. Care Med. 2000; 161: 996–1001.

9. Miller-Larsson A., Mattsson H., Hjertberg E. et al. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metabol. Disposit. 1998; 26: 623–630.

10. Brattsand R., Miller2Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin. Ther. 2003; 25: 28–41.

11. Miller-Larsson A., Jansson P., Runstrom A., Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am. J. Respir. Crit. Care Med. 2000; 162: 1455–1461.

12. Derom E., Van Schoor J., Verhaeghe W. et al. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 157–161.

13. Boorsma M., Andersson N., Larsson P., Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur. Respir. J. 1996; 9 (7): 1427–1432.

14. Grimfeld A. et al. Longterm study of nebulised budesonide in young children with moderate to severe asthma. Eur. Respir. J. 1994; 7: 27S.

15. Foresi A., Morelli M.C., Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000; 117: 440–446.

16. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. 1993; 52 (26): 2145–2160.

17. Palmqvist M., Ibsen T., Mellen A., Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med.,1999; 160 (1): 244–249.

18. van Noord J.A., Smeets J.J., Raaijmakers J.A. et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur. Respir. J. 1996; 9: 1684–1648.

19. Nials A.T., Ball D.I., Butchers P.R. et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur. J. Pharmacol. 1994; 251: 127–135.

20. Molimard M., Naline E., Zhang Y. et al. Longand shortadrenoreceptor agonists: interactions in human contracted bronchi. Eur. Respir. J., 1998; 11: 583–588.

21. O'Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the non-bronchodilatator effects of inhaled b2-agonists in asthma. N. Engl. J. Med., 1992; 327: 1204–1208.

22. Hall Ian P. Hall. β2 -adrenoreceptor agonists. In: Barnes P.J. Asthma and COPD basic mechanisms and clinical management. 1st ed. NewYork: Academic Press; 2002.

23. Brambilla C., Le Gros V., Bourdeix I. et al. Formoterol 12 BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or ondemand salbutamol: a multicenter, randomized, open-label, parallel-group study. Clin. Ther. 2003; 25 (7): 2022–2036.

24. Politiek M.J., Boorsma M., Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholineinduced severe bronchoconstriction. Eur. Respir. J. 1999; 13: 988–992.

25. Pauwels R.A., Sears N.R., Cambell M. et al. Formoterol as relief medication in asthma: a world safety and effectiveness trial. Eur. Respir. J. 2003; 22: 787–794.

26. Tattersfield A.E., Lofdahl C.2G., Postma D.S. et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised controlled trial. Lancet 2001; 357: 257–261.

27. Gibson P.G., Saltos N., Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma. A randomized controlled trial. Am. J. Respir. Crit. Care Med. 2001; 163: 32–36.

28. Stallberg B., Olsson P., Jorgensen L.A. et al. Budesonide / formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int. J. Clin. Pract. 2003; 57 (8): 656–661.

29. Aalbers R., Backer V., Kava T.T.K. et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Cur. Med. Res. Opin. 2004; 20 (2): 225–240.

30. Ankerst J., Persson G., Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients. Eur. Respir. J. 2000; 16 (suppl. 31): 33s+poster.

31. O'Byrne P.M., Bisgaard H., Godard P.P. et al. Budesonide / formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 129–136.

32. Kuna P., Peters M.J., Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. Abstract presented at the ERS Congress 2006.

33. Rabe K., Atienza T., Magyar P. et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised, controlled, double-blind study. Lancet 2006; 368: 744–753.

34. Vogelmeier C., D'Urzo A., Pauwels R. et al. Budesonide / formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J. 2005; 26 (5): 819–828.

35. Scicchitano R., Aalbers R., Ukena D. et al. Efficacy and safety of budesonide / formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Cur. Med. Res. Opin. 2004; 20 (9): 1403–1418.

36. Rabe K.F., Pizzichini E., Stallberg B. et al. Budesonide / formoterol in a single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma: A Randomized, double-blind trial. Chest 2006; 129: 246–256.


Для цитирования:


Княжеская Н.П. Будесонид / формотерол – ингалятор для базисного лечения и купирования симптомов бронхиальной астмы (стратегия SMART). Пульмонология. 2007;(6):87-92. https://doi.org/10.18093/0869-0189-2007-0-6-87-92

For citation:


Knyazheskaya N.P. Budesonide / formoterol as an inhaler for basic therapy and relief of asthma symptoms (SMART strategy). PULMONOLOGIYA. 2007;(6):87-92. (In Russ.) https://doi.org/10.18093/0869-0189-2007-0-6-87-92

Просмотров: 13


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)